METHACHOLINE CHLORIDE, USP POWDER FOR SOLUTION

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

METHACHOLINE CHLORIDE

Dostupné z:

PANDA PHARMACEUTICALS INC.

ATC kód:

V04CX

INN (Medzinárodný Name):

OTHER DIAGNOSTIC AGENTS

Dávkovanie:

160MG

Forma lieku:

POWDER FOR SOLUTION

Zloženie:

METHACHOLINE CHLORIDE 160MG

Spôsob podávania:

INHALATION

Počet v balení:

20ML

Typ predpisu:

Prescription

Terapeutické oblasti:

OTHER DIAGNOSTIC AGENTS

Prehľad produktov:

Active ingredient group (AIG) number: 0136042004; AHFS:

Stav Autorizácia:

APPROVED

Dátum Autorizácia:

2017-09-15

Súhrn charakteristických

_Page 1 of 30 _
PRODUCT MONOGRAPH
PR
METHACHOLINE CHLORIDE, USP
Powder for inhalation solution
100 mg, 160 mg, 320 mg, 1280 mg and 1600 mg
Cholinergic / Diagnostic Aid (Bronchial Asthma)
Date of Preparation:
September 14, 2017
PANDA Pharmaceuticals.
35 Nixon Road
Caledon, Ontario
L7E 1K1
Control #204408
_Page 2 of 30 _
TABLE OF CONTENTS
PART
I
:
HEALTH PROFESSIONAL INFORMATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL
USE.........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
..............................................................................................................................
7
DRUG INTERACTIONS
...............................................................................................................................
7
DOSAGE AND ADMINISTRATION
...........................................................................................................
8
OVERDOSAGE
...........................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................
20
STORAGE AND STABILITY
....................................................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
..................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
................